This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Purpura, Thrombocytopenic, Idiopathic
and you are
between 16 and 75
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).

Provided treatments

  • Drug: rhIL-11

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01317966. The sponsor of the trial is Ming Hou and it is looking for 0 volunteers for the current phase.
Official trial title:
A Multicentre Investigation of Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)